Semaglutide and tirzepatide significantly reduced BMI in non-diabetic IBD patients (median 8.15 kg loss) with manageable side effects and no apparent worsening of inflammatory markers.
8.15 kg median weight lossNon-diabetic IBD patients lost a median of 8.15 kg on GLP-1 agonists with no worsening of inflammatory markers — the first evidence of safety and efficacy in this unique population
What the researchers found
BMI decreased significantly from 34.0 to 31.0 (p<0.0001) with median weight loss of 8.15 kg (p<0.0001). CRP and ALT levels did not change significantly, suggesting no worsening of IBD inflammation. Total cholesterol and HbA1c showed trends toward improvement. Side effects: nausea (31%), constipation (25%).
Why it matters
IBD patients with obesity face unique challenges — their gut inflammation may interact with weight loss drugs in unpredictable ways, and concerns about GI side effects are amplified. This study provides the first evidence that GLP-1 agonists are both effective and apparently safe in IBD, filling an important clinical evidence gap.
The numbers in context
Patients received semaglutide or liraglutide. The study tracked weight loss and metabolic parameters alongside IBD activity measures.
How the study worked
Single-center observational cohort study of 36 adult IBD patients (non-diabetic) started on semaglutide or tirzepatide for weight loss between January 2021 and April 2024. Primary outcomes: BMI and total body weight changes. Secondary outcomes: tolerability, safety, metabolic risk factors.
Who was studied
Non-diabetic adults with IBD starting GLP-1 therapy for weight loss
What this study cannot tell us
Very small sample (36 patients) from a single center. Observational design without a control group. Short follow-up period. Did not specifically assess IBD disease activity scores (only CRP). The study couldn't differentiate between semaglutide and tirzepatide effects. 86% of patients were already on advanced IBD therapy, which may have masked any inflammatory effects.
How to read the evidence
Preliminary evidence from a small, single-center observational study without a control group. Important as first-of-kind data in IBD patients, but requires validation in larger controlled trials.
When this study was published
Published in 2024, providing timely evidence as GLP-1 agonist prescribing rapidly expands and clinicians encounter more IBD patients requesting these medications.
The bigger picture
The intersection of obesity and IBD is a growing clinical challenge. Obesity worsens IBD outcomes, yet many weight loss interventions are concerning for patients with compromised gut function. These early data suggesting GLP-1 agonists work without worsening IBD are encouraging and may influence treatment guidelines for this growing patient population.
Questions still open
- Do GLP-1 agonists have anti-inflammatory effects in the gut that could independently benefit IBD patients?
- Are there IBD-specific risks with long-term GLP-1 agonist use, such as effects on intestinal absorption or microbiome?
Common questions
Is it safe to take semaglutide if I have Crohn's disease or ulcerative colitis?
Could GLP-1 drugs actually help IBD?
Read the original research
Efficacy and Safety of GLP-1 Agonists on Metabolic Parameters in Non-diabetic Patients with Inflammatory Bowel Disease.
Digestive diseases and sciences, 69(12), 4437-4445
Citation
St-Pierre, Joëlle; Klein, Jeremy; Choi, Natalie K; Fear, Evan; Pannain, Silvana; Rubin, David T. (2024). Efficacy and Safety of GLP-1 Agonists on Metabolic Parameters in Non-diabetic Patients with Inflammatory Bowel Disease.. Digestive diseases and sciences, 69(12), 4437-4445. https://doi.org/10.1007/s10620-024-08720-2